Research Topics
Genomes and Genes | Hai YanSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolismZachary J Reitman
Department of Pathology, The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
J Natl Cancer Inst 102:932-41. 2010..Study of alterations in these metabolic enzymes may provide insights into the metabolism of cancer cells and uncover novel avenues for development of anticancer therapeutics...- IDH1 and IDH2 mutations in gliomasHai Yan
Department of Pathology, Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
N Engl J Med 360:765-73. 2009.... - Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolomeZachary J Reitman
The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 108:3270-5. 2011..NAAG also was significantly lower in human glioma tissues containing IDH mutations than in gliomas without such mutations. These metabolic changes provide clues to the pathogenesis of tumors associated with IDH gene mutations... - 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutationsGenglin Jin
The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, and Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America
PLoS ONE 6:e16812. 2011..Genetic evidence indicates that these mutations share a common gain of function, but it is unclear whether the shared function is dominant negative activity, neomorphic production of (R)-2-hydroxyglutarate (2HG), or both... - HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosoureaGenglin Jin
Department of Pathology, Pediatric Brain Tumor Foundation Institute and Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina 27710, USA
Neuro Oncol 12:956-66. 2010..In summary, HDMX exhibits bona fide oncogenic properties and offers a promising molecular target for GBM therapeutic intervention... - Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genesChristopher G Duncan
The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation, The Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
Oncotarget 1:265-77. 2010..Our multifaceted genomic evaluation of glioblastoma establishes ERRFI1 as a potential candidate tumor suppressor gene and TACC3 as a potential oncogene, and provides insight on targets for oncogenic pathway-based therapy... - Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stressZheming Lu
Department of Pathology, The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 69:9105-11. 2009.... - OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomasDavid C Adamson
Department of Surgery, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Veterans Affairs Medical Center, Durham, North Carolina 27710, USA
Cancer Res 70:181-91. 2010..Mechanistic investigations revealed upregulation of MYC as a potential mechanism whereby OTX2 promotes tumor progression. Our findings define OTX2 as an important oncogenic driver in medulloblastoma... - Mutant IDH1 is required for IDH1 mutated tumor cell growthGenglin Jin
The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation Institute, and the Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
Oncotarget 3:774-82. 2012..Our findings offer insights into changes that may contribute to the inhibition of cell proliferation and offer a strong preclinical rationale for utilizing mutant IDH1 as a valid therapeutic target... 
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acidChunhui Di
Brain Tumor Center, Department of Pathology, Duke University Medical Center, Research Drive, Durham, NC 27710, USA
Cancer Res 65:919-24. 2005..These observations suggest that OTX2 is essential for the pathogenesis of anaplastic medulloblastomas and that these tumors may be amenable to therapy with all-trans-retinoic acid...- IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brainGiselle Y Lopez
The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation, and the Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
Biochem Biophys Res Commun 398:585-7. 2010..Studies on the cell-lineages of tumors with IDH1/2 mutations may help clarify the role of these mutations in the development of brain tumors... - Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cellsMatthew Wortham
Department of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, USA
PLoS ONE 7:e36211. 2012..These studies implicate a role for Otx2 in altering the dynamics of neuronal progenitor cell proliferation... 
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic targetChangcun Guo
The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
Curr Opin Neurol 24:648-52. 2011..The mechanisms of IDH mutations in gliomagenesis, and their value as diagnostic, prognostic marker and therapeutic target have been extensively studied. This review is to summarize the findings of these studies...- A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutationYukinari Kato
Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
Biochem Biophys Res Commun 390:547-51. 2009..In conclusion, we established an anti-IDH1(R132H)-specific monoclonal antibody IMab-1, which should be significantly useful for diagnosis and biological evaluation of mutation-bearing gliomas... - Mutant metabolic enzymes are at the origin of gliomasHai Yan
The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina, USA
Cancer Res 69:9157-9. 2009..IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors... - A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylationChristopher G Duncan
The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation Institute, The Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
Genome Res 22:2339-55. 2012..These data provide insight on epigenetic alterations induced by IDH1 mutations and support a causal role for IDH1(R132H/WT) mutants in driving epigenetic instability in human cancer cells... - Apples to origins: identifying brain tumor stem cell genes by comparing transcriptomes of normal and cancer stem cellsMatthew Wortham
Department of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Discov 2:492-4. 2012.... - Glioblastoma multiforme: a review of therapeutic targetsOkezie O Kanu
Duke and Durham VAMC, Neurosurgery, DUMC Box 2624, NC 27710, USA
Expert Opin Ther Targets 13:701-18. 2009..This review describes the epidemiology, clinical presentation, pathology and tumor immunology, with a focus on understanding the molecular biology that underlies the current targeted therapeutics being tested... - Allelic variations in gene expressionHai Yan
Duke University Medical Center, Department of Pathology, Durham, North Carolina 27710, USA
Curr Opin Oncol 16:39-43. 2004..Thus, it has been hypothesized that the study of natural differential expression presenting within and among populations may enhance understanding of human phenotypic variation... - Enzyme redesign guided by cancer-derived IDH1 mutationsZachary J Reitman
Department of Pathology, Duke University Medical Center, Durham, NC, USA
Nat Chem Biol 8:887-9. 2012..Thus, we provide a prototypic example of how insights from cancer genome sequencing and functional studies can aid in enzyme redesign... - Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathwaysChangcun Guo
The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, cDepartment of Pathology, Duke University, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 109:17603-8. 2012..Our results present a genome-wide integrative analysis of the MLL2 target loci and suggest potential mechanisms underlying tumorigenesis driven by MLL2 alterations... - Digital karyotyping technology: exploring the cancer genomeTimothy J Parrett
Department of Pathology, Brain Tumor Center, Duke University Medical Center, 3156, Durham, NC 27710, USA
Expert Rev Mol Diagn 5:917-25. 2005.... - Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomasDaniel K Broderick
Brain Tumor Center, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
Cancer Res 64:5048-50. 2004..These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers... - Altered telomeres in tumors with ATRX and DAXX mutationsChristopher M Heaphy
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
Science 333:425. 2011..ATRX mutations also correlate with abnormal telomeres in tumors of the central nervous system. These data suggest that an alternative telomere maintenance function may operate in human tumors with alterations in the ATRX or DAXX genes... - IDH1 and IDH2: not your typical oncogenesZachary J Reitman
The Preston Robert Tisch Brain Tumor Center at Duke, The Pediatric Brain Tumor Institute, and the Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
Cancer Cell 17:215-6. 2010..However, seemingly oncogenic mutations in IDH1 and IDH2 reduce their native enzyme activity. In this issue of Cancer Cell, Ward et al. pin down a neomorphic enzyme activity as a possible oncogenic function for these alterations... - Identification of microbial DNA in human cancerChristopher G Duncan
Preston Robert Tisch Brain Tumor Center, Pediatric Brain Tumor Foundation Institute, Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
BMC Med Genomics 2:22. 2009..CONCLUSION: DK-MICROBE can identify previously unknown infectious agents in human tumors, and is now available for further applications for the identification of pathogen DNA in human cancer and other diseases... - Snapshot of the allele-specific variation in human gene expressionHai Yan
Department of Pathology, Duke University Meeical Center, Durham, NC, USA
Methods Mol Biol 311:31-8. 2005..The studies of allele-specific expression revealed that differential expression is relatively common in the human population...